Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | PPARG | P37231 | 1/20 | 0.59 |
| ▸ | PPARA | Q07869 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CCKAR | P32238 | 1/20 | 0.50 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6643092 | 0.94 | PPARG (0.63) | LDHAPPARGPPARAEPHX1KMT2A | |
| SCHEMBL21959088 | 0.93 | LDHA (0.69) | LDHAPPARGPPARACCKAR | |
| SCHEMBL27871541 | 0.90 | LDHA (0.60) | LDHAPPARGPPARAATMMMP1 | |
| SCHEMBL23494950 | 0.88 | ESR1 (0.63) | LDHAPPARGPPARAATMMMP1 | |
| SCHEMBL10964998 | 0.88 | ESR1 (0.63) | LDHAPPARGPPARA | |
| SCHEMBL4506554 | 0.88 | EPHX1 (0.71) | LDHAPPARGPPARAATMMMP1 | |
| SCHEMBL6588762 | 0.88 | LDHA (0.57) | LDHAPPARGPPARAATMMMP1 | |
| SCHEMBL1153337 | 0.86 | LDHA (0.59) | LDHAPPARGPPARAKMT2AMEN1 | |
| SCHEMBL29174149 | 0.86 | LDHA (0.59) | LDHAPPARGPPARAKMT2AMEN1 | |
| SCHEMBL2922282 | 0.86 | MITF (0.59) | LDHAPPARGPPARAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689849-B1 | PERFUME PRECURSOR | TAKASAGO PERFUMERY CO LTD (JP) | 2025-01-15 | — | — | EP | claimed |
| US-20160090556-A1 | PRODUCTS COMPRISING MALODOR REDUCTION MATERIALS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | claimed |
| EP-1716159-B1 | BICYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS | MOMENTIVE PERFORMANCE MAT INC (US) | 2011-07-13 | — | — | EP | claimed |
| EP-1697386-B1 | ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES | GEN ELECTRIC (US) | 2007-10-10 | — | — | EP | claimed |
| EP-3704117-B1 | AZABICYCLO DERIVATIVES FOR TREATING OCULAR DISORDERS | ALCON INC (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-12247028-B2 | Azabicyclo and diazepine derivatives | ALCON INC. (CH) | 2025-03-11 | — | — | US | disclosed |
| EP-4016044-B1 | IMPROVED METHOD FOR OPTICALLY CLARIFYING A TISSUE SAMPLE FOR MICROSCOPIC EXAMINATION | MobiCron GmbH (DE) | 2025-02-05 | — | — | EP | disclosed |
| US-20240132497-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2024-04-25 | — | — | US | disclosed |
| US-11884666-B2 | Azabicyclo and diazepine derivatives | ALCON INC. (CH) | 2024-01-30 | — | — | US | disclosed |
| CN-107847958-B | Switchable digital scent generation and release and vapor and liquid delivery methods and systems | 加利福尼亚大学董事会 | 2024-01-16 | — | — | CN | disclosed |
| US-20220267328-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | ALCON INC. (CH) | 2022-08-25 | — | — | US | disclosed |
| WO-2022129221-A1 | IMPROVED METHOD FOR OPTICALLY CLEARING A TISSUE SAMPLE FOR A LIGHT MICROSCOPY EXAMINATION | MobiCron GmbH (DE) | 2022-06-23 | — | — | WO | disclosed |
| EP-1261588-A1 | NEW IMIDAZOLE DERIVATIVES | ORION CORPORATION (FI) | 2002-12-04 | — | — | EP | disclosed |
| US-20020115621-A1 | Macrolide antibiotics | PFIZER INC. | 2002-08-22 | — | — | US | disclosed |
| US-6388090-B2 | IMIDAZOLE DERIVATIVES CONTAINING BICYCLIC AROMATIC OR AN HETEROCYCLIC RING FUSED WITH BENZENE EXHIBIT AFFINITY FOR ALPHA2 ADRENOCEPTORS SO TREATS THE DISEASE AFFECTED BY ALPHA2 ADRENOCEPTORS, E.G. NUROLOGICAL, PSYCHIATRIC OR COGNITION | ORION CORPORATION (FI) | 2002-05-14 | — | — | US | disclosed |
| WO-2002012260-A1 | MACROLIDE ANTIBIOTICS | PFIZER PRODUCTS INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| US-20010056109-A1 | Imidazole derivatives | ORION CORPORATION (FI) | 2001-12-27 | — | — | US | disclosed |
| CN-1314906-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-09-26 | — | — | CN | disclosed |
| WO-2001051472-A1 | NEW IMIDAZOLE DERIVATIVES | ORION CORPORATION (FI) | 2001-07-19 | — | — | WO | disclosed |
| US-5776983-A | ANTIDIABETIC AGENTS, OBESITY, GASTROINTESTINAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884666-B2 | Azabicyclo and diazepine derivatives | CHRM3, CHRM5, CHRNA5 | LDHA 4752/4885PPARG 410/4885PPARA 633/4885 |
| US-20010056109-A1 | Imidazole derivatives | ADRB2, ADRB1, ADRA1D | LDHA 3424/4885PPARG 1300/4885PPARA 2296/4885 |
| US-20240132497-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | CHRM3, CHRM5, CHRNA5 | LDHA 4752/4885PPARG 410/4885PPARA 633/4885 |
| US-20020115621-A1 | Macrolide antibiotics | MRPL21, NOP2, NPPA | LDHA 2182/4885PPARG 2738/4885PPARA 2436/4885 |
| US-20220267328-A1 | AZABICYCLO AND DIAZEPINE DERIVATIVES | CHRM3, CHRM5, CHRNA5 | LDHA 4752/4885PPARG 410/4885PPARA 633/4885 |
| US-12247028-B2 | Azabicyclo and diazepine derivatives | CHRM3, CHRM5, CHRNA5 | LDHA 4752/4885PPARG 410/4885PPARA 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.